Is There Already a Need of Reckoning on Cancer Immunotherapy?

Is There Already a Need of Reckoning on Cancer Immunotherapy?

Bibliographische Detailangaben
Hauptverfasser:	Pierpaolo Correale, Francesca Pentimalli, Giovanni Baglio, Marjia Krstic-Demonacos, Rita Emilena Saladino, Antonio Giordano, Luciano Mutti
Format:	Artikel
Sprache:	English
Veröffentlicht:	Frontiers Media S.A. 2021-03-01
Schriftenreihe:	Frontiers in Pharmacology
Schlagworte:	immunotherapy cancer study design real world evidences mesothelioma
Online Zugang:	https://www.frontiersin.org/articles/10.3389/fphar.2021.638279/full

Ähnliche Einträge

Coronavirus Disease (Covid-19): What Are We Learning in a Country With High Mortality Rate?
von: Luciano Mutti, et al.
Veröffentlicht: (2020-05-01)

Immune Checkpoint Inhibitor Uptake in Real-World Patients With Malignant Pleural Mesothelioma
von: Roger Y. Kim, MD, et al.
Veröffentlicht: (2021-06-01)

Intratumor microbiota as a novel potential prognostic indicator in mesothelioma
von: Francesca Pentimalli, et al.
Veröffentlicht: (2023-03-01)

Current status and progress in immunotherapy for malignant pleural mesothelioma
von: Boyang Sun, et al.
Veröffentlicht: (2022-06-01)

Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis
von: Valerio Nardone, et al.
Veröffentlicht: (2021-11-01)

The therapeutic potential of the novel ribonuclease ranpirnase (Onconase®) in the treatment of malignant mesothelioma
von: Luciano Mutti, et al.
Veröffentlicht: (2011-12-01)

The therapeutic potential of the novel ribonuclease ranpirnase (Onconase®) in the treatment of malignant mesothelioma
von: Luciano Mutti, et al.
Veröffentlicht: (2011-12-01)

Targeted therapy and immunotherapy for malignant mesothelioma
Veröffentlicht: (2024-10-01)

The Role of Immunotherapy in the Treatment of Malignant Pleural Mesothelioma
von: Shantanu Banerji, et al.
Veröffentlicht: (2021-11-01)

How to Increase the Efficacy of Immunotherapy in NSCLC and HNSCC: Role of Radiation Therapy, Chemotherapy, and Other Strategies
von: Valerio Nardone, et al.
Veröffentlicht: (2018-12-01)

A rare presentation of malignant mesothelioma of the tunica vaginalis managed with immunotherapy and review of the literature
von: Kritika Mishra, et al.
Veröffentlicht: (2023-06-01)

Sirtuin Family Members Selectively Regulate Autophagy in Osteosarcoma and Mesothelioma Cells in Response to Cellular Stress
von: Richa Garva, et al.
Veröffentlicht: (2019-09-01)

Epigenetic Immune Remodeling of Mesothelioma Cells: A New Strategy to Improve the Efficacy of Immunotherapy
von: Maria Fortunata Lofiego, et al.
Veröffentlicht: (2021-12-01)

CAR T-cell immunotherapy of MET-expressing malignant mesothelioma
von: Thivyan Thayaparan, et al.
Veröffentlicht: (2017-12-01)

Pathological complete response in a patient with pleural mesothelioma treated with immunotherapy: a case report
von: Eleonora Faccioli, et al.
Veröffentlicht: (2024-04-01)

Case report: complete response and long-term survival on third-line immunotherapy in patient with pleural mesothelioma
von: Željka Jurić Čuljak, et al.
Veröffentlicht: (2024-08-01)

Advances in Immunotherapy for Malignant Pleural Mesothelioma
von: Yujia CHI, et al.
Veröffentlicht: (2022-04-01)

Potential treatment approaches for malignant peritoneal mesothelioma: in vivo and in vitro experimental study of natural killer cell immunotherapy
von: Heliang Wu, et al.
Veröffentlicht: (2024-11-01)

An Update on Emerging Therapeutic Options for Malignant Pleural Mesothelioma
von: Davis A, et al.
Veröffentlicht: (2022-03-01)

Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: Work still in progress
von: Matteo Perrino, et al.
Veröffentlicht: (2023-01-01)

Pleural mesothelioma (PMe): The evolving molecular knowledge of a rare and aggressive cancer
von: Manuel Rigon, et al.
Veröffentlicht: (2024-04-01)

The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy
von: Gerard J. Chu, et al.
Veröffentlicht: (2019-12-01)

Targeting FAcilitates Chromatin Transcription complex inhibits pleural mesothelioma and enhances immunotherapy
von: Anand Singh, et al.
Veröffentlicht: (2023-11-01)

Immunotherapy in Malignant Pleural Mesothelioma
von: Cornedine J. de Gooijer, et al.
Veröffentlicht: (2020-02-01)

Current Landscape of Immunotherapy Trials Involving the Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Axis in Intrathoracic Tumors
von: Samuel A. Kareff, MD, MPH, et al.
Veröffentlicht: (2021-04-01)

Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer Under-Represented by Clinical Trials
von: Daniel E. Meyers, et al.
Veröffentlicht: (2024-09-01)

Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream
von: Luana Calabrò, et al.
Veröffentlicht: (2024-01-01)

A trial of intra-pleural bacterial immunotherapy in malignant pleural mesothelioma (TILT) — a randomised feasibility study using the trial within a cohort (TwiC) methodology
von: Anna C. Bibby, et al.
Veröffentlicht: (2022-09-01)

Combining a WT1 Vaccine (Galinpepimut-S) With Checkpoint Inhibition (Nivolumab) in Patients With WT1–Expressing Diffuse Pleural Mesothelioma: A Phase 1 Study
von: Prashasti Agrawal, MD, et al.
Veröffentlicht: (2025-01-01)

Comparative efficacy of immune checkpoint inhibitors versus chemotherapy alone in diffuse pleural mesothelioma
von: Xuemei Zhang, et al.
Veröffentlicht: (2024-07-01)

The Oncolytic Virus dl922-947 Triggers Immunogenic Cell Death in Mesothelioma and Reduces Xenograft Growth
von: Sarah Di Somma, et al.
Veröffentlicht: (2019-07-01)

Real-World Adherence and Evidence of Subcutaneous and Sublingual Immunotherapy in Grass and Tree Pollen-Induced Allergic Rhinitis and Asthma
von: Vogelberg C, et al.
Veröffentlicht: (2020-05-01)

Diffuse Peritoneal Malignant Mesothelioma Presenting with Abnormal Uterine Bleeding: Case Report
von: Ivana Rizzuto, et al.
Veröffentlicht: (2022-03-01)

Multi-antigen Vaccination With Simultaneous Engagement of the OX40 Receptor Delays Malignant Mesothelioma Growth and Increases Survival in Animal Models
von: Peter R. Hoffmann, et al.
Veröffentlicht: (2019-08-01)

Complete Pathological Response After Neoadjuvant Chemo-Immunotherapy in Malignant Pleural Mesothelioma
von: Francinne T. Tostes, et al.
Veröffentlicht: (2022-04-01)

Evaluation of prognostic histological parameters proposed for pleural mesothelioma in diffuse malignant peritoneal mesothelioma. A short report
von: Federica Pezzuto, et al.
Veröffentlicht: (2021-07-01)

Sublingual grass allergen specific immunotherapy: a retrospective study of clinical outcome and discontinuation
von: Christer Janson, et al.
Veröffentlicht: (2018-06-01)

Long-term health care resource and cost savings with allergy immunotherapy: REACT study results
von: Benedikt Fritzsching, MD, et al.
Veröffentlicht: (2024-02-01)

Unusual Histology in Mesothelioma: A Report of Two Cases with a Brief Review
von: Francesca Bono, et al.
Veröffentlicht: (2022-02-01)

DNA methylation status classifies pleural mesothelioma cells according to their immune profile: implication for precision epigenetic therapy
von: Maria Fortunata Lofiego, et al.
Veröffentlicht: (2025-02-01)